These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15696286)

  • 1. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Griebenow R
    Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
    [No Abstract]   [Full Text] [Related]  

  • 2. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
    [No Abstract]   [Full Text] [Related]  

  • 5. Study suggests statins for diabetics with healthy LDL cholesterol levels.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Sep; 15(18):1-2, 6-7. PubMed ID: 15452942
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 7. [AVERT [The Atorvastatin versus Revascularization Treatment]].
    Mokuno H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():436-41. PubMed ID: 11347110
    [No Abstract]   [Full Text] [Related]  

  • 8. Journal Watch: evidence that Atorvastatin reduces the risk of stroke and myocardial infarction in patients with type 2 diabetes, but with no evidence of dyslipidaemia.
    Gangaidzo IT
    Cent Afr J Med; 2005; 51(11-12):125-6. PubMed ID: 17447346
    [No Abstract]   [Full Text] [Related]  

  • 9. Statins for high-risk patients without heart disease or high cholesterol.
    Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
    Constance C; Westphal S; Chung N; Lund M; McCrary Sisk C; Johnson-Levonas AO; Massaad R; Allen C
    Diabetes Obes Metab; 2007 Jul; 9(4):575-84. PubMed ID: 17451425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoid angioplasty by lowering cholesterol?
    Health News; 1999 Aug; 5(10):5. PubMed ID: 15352287
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
    Lafuma A; Colin X; Solesse A
    Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and CVD prevention in the diabetic population: implications of the CARDS trial.
    Murad O; Palmer J; Sowers J; McFarlane SI
    Curr Diab Rep; 2005 Jun; 5(3):191-3. PubMed ID: 15929865
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and residual risk of coronary heart disease.
    Nesto RW; Singh PP
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):71. PubMed ID: 17237830
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of lipid management in diabetes.
    Ganda OP
    Cardiol Clin; 2005 May; 23(2):153-64, vi. PubMed ID: 15694744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.